Results of a multicenter comparative study of the efficacy and safety of therapy with 0.03% bimatoprost and 0.004% travoprost

PURPOSE: To evaluate and compare the intraocular pressure changes in patients with initial and advanced stages of open-angle glaucoma (POAG) when using the study drug bimatoprost 0.03% and the comparison drug travoprost 0.004%, as well as to assess the effect of these drugs on the ocular surface.
METHODS: The study involved 81 patients (137 eyes), 48 women and 23 men, with a mean age of 63 years. Patients of the first group (36 patients, 69 eyes) received 0.03% bimatoprost for 3 months. Patients of the second group (35 patients, 68 eyes) received 0.004% travoprost for 3 months.
RESULTS: According to tonometry data, a hypotensive effect was observed in both groups. Regardless of the method of tonometry, intraocular pressure was lower in the group of patients receiving 0.03% bimatoprost (p<0.001).
In both groups, the state of the anterior segment of the eye was affected in the form of increased hyperemia and an increase in spot staining of the cornea and conjunctiva with fluorescein according to the Oxford scale. However, there was no significant differences between the action of 0.03% bimatoprost and 0.004% travoprost drugs.
CONCLUSION: The hypotensive effect of bimatoprost 0.03% was better than travoprost 0.004%. Both drugs had an effect on the ocular surface. The incidence of adverse events in the group of patients treated with bimatoprost did not exceed similar results for travoprost.

1. Egorov E.A., Astakhov Yu.S., Yerichev V.P. Nacional'noe rukovodstvo po glaukome. [National Guidelines for Glaucoma]. 2015.

2. Astakhov Yu.S., Akopov A.L., Potemkin V.V. Comparative characteristics of modern tonometry methods. Vestn Oftalmol. 2008; 5:11-14.

3. Camras C., Alm A., Watson P. Glaucoma treatment for 1 year with latanoprost, a prostaglandin analog, in the USA, Scandinavia and UK. American Academy of Ophthalmology, Annual Meeting: Atlanta; 1995. 89.

4. World Health Organization. Division of Drug Management and Policies. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for a drug regulatory authority. World Health Organization. 1999. https://apps.who.int/iris/handle/10665/65175

5. Linden C. et al. Prostaglandin analogues in the treatment of glaucoma. Drugs and Aging. 1999; 14:387-398.

6. Schuman J.S. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther. 2000; 22:167-208.

7. Eisenberg D.L. et al. A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. Drug Safety. 1999; 20:505-514.

8. Gandolfi S. et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Advances in Therapy. 2001; 18:110-121.

9. Susanna R. et al. The pros and cons of different prostanoids in the medical management of glaucoma. Curr Opin Ophthalmol. 2001; 12:149-156.